Search

Search Results

• 

  2024 EACTS guidelines on perioperative medication in adult cardiac surgery: embracing precision medicine driven by strong evidence-based methodology

  Bianca Rocca, Emma Hansson, Milan Milojevic, Anders Jeppsson

  01-07-2025

  https://doi.org/10.4081/btvb.2025.178

  2038

  PDF: 629
• 

  The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey

  Silvia Linari, Renato Marino, Marzia Leotta, Antonio Coppola, Patrizia Di Gregorio, Augusto Bramante Federici, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro

  05-11-2025

  https://doi.org/10.4081/btvb.2025.369

  1077

  PDF: 146

  HTML: 44

  Appendix: 79
• 

  Anticoagulation in obese patients: challenges and strategies

  Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia

  18-09-2025

  https://doi.org/10.4081/btvb.2025.174

  1869

  PDF: 279

  HTML: 204

  XML: 88
• 

  Executive summary of the SISET position paper on the management of antithrombotic therapy in left ventricular thrombus

  Emanuele Valeriani, Arianna Pannunzio, Danilo Menichelli, Domenico Prisco, Walter Ageno, Daniele Pastori, Pasquale Pignatelli

  16-12-2025

  https://doi.org/10.4081/btvb.2025.401

  282

  PDF: 68

  HTML: 23
• 

  Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers

  Renato Marino, Silvia Linari, Marzia Leotta, Antonio Coppola, Chiara Biasoli, Maria Elisa Mancuso, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro

  02-12-2025

  https://doi.org/10.4081/btvb.2025.372

  454

  PDF: 68

  HTML: 53

  Supplementary: 30

  Appendix: 46
• 

  The night of randomized clinical trials where all patients are black: a need to estimate variability in treatment effects

  Giovanni de Gaetano, Chiara Cerletti, Licia Iacoviello, Maria Benedetta Donati

  22-03-2022

  https://doi.org/10.4081/btvb.2022.24

  2182

  PDF: 344
• 

  PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani¹, C. Séguin² | ¹Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; ²Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.524

  113

  PDF: 29
• 

  Anticoagulation during anti-angiogenic cancer therapy: balancing risks of thrombosis and bleeding

  Nikola Vladic, Florian Moik

  16-04-2026

  https://doi.org/10.4081/btvb.2026.452

  103

  PDF: 61
• 

  Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy

  Gary E. Raskob

  16-05-2024

  https://doi.org/10.4081/btvb.2024.124

  1361

  PDF: 855
• 

  Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey

  Stefania Cavazza, Gualtiero Palareti*

  03-10-2025

  https://doi.org/10.4081/btvb.2025.177

  1315

  PDF: 238

  HTML: 92

  Supplementary: 70
• 

  Anticoagulation challenges in patients with hematological malignancy-associated thrombosis and severe thrombocytopenia

  Emilie Chalayer, Géraldine Poenou, Corinne Frere

  16-04-2026

  https://doi.org/10.4081/btvb.2026.429

  96

  PDF: 60
• 

  Attitude to clinical research among health professionals affiliated with the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA)

  Daniela Poli, Riccardo Tartaglia, Doris Barcellona , Paolo Bucciarelli , Antonio Ciampa, Elvira Grandone, Giuseppe Malcangi, Giuseppe Rescigno, Vincenzo Toschi, Sophie Testa, Alessandro Squizzato

  21-03-2023

  https://doi.org/10.4081/btvb.2023.59

  1040

  PDF: 327
• 

  PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven^1|9, E. Van Gansewinkel^5|10, J. De Bruijne², F. Eskens³, D. De Groot⁴, K. Hermans⁵, N. Mohammad⁶, F. Van Vilsteren⁷, C. Verslype⁸, W. Moris⁹, M. Roest¹⁰, B. De Laat¹⁰ , J. De Vos-Geelen⁵, M. Kramer^1|9 | ¹Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ²Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; ³Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; ⁴Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; ⁵Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ⁶Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; ⁷Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; ⁸Digestive Oncology, University Hospitals Leuven, Belgium; ⁹Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; ¹⁰Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.554

  107

  PDF: 20